MT-101 / CREATE Medicines - LARVOL DELTA

IMAGINE: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (clinicaltrials.gov) - P1/2 | N=40 | Suspended | Sponsor: Myeloid Therapeutics

Trial completion date • Trial primary completion date • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • CD5

IMAGINE: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (clinicaltrials.gov) - P1/2 | N=40 | Suspended | Sponsor: Myeloid Therapeutics | Recruiting ➔ Suspended

Trial suspension • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • CD5

Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline (PRNewswire) - "Myeloid Therapeutics...announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from new investors ARCH Venture Partners and Moore Strategic Ventures. All existing investors, including Newpath Partners, 8VC and Alexandria Venture Investments, also participated....Proceeds from the financing will support the continued clinical development of MT-101, Myeloid's lead cell therapy program in Phase 1/2 for T cell lymphoma, and will accelerate the development of MT-302, a first-in-class TROP2-FcA mRNA-LNP product, into a Phase 1/2 study for TROP2-expressing tumors."

Financing • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Initial preclinical and clinical experience of autologous engineered monocytes in T cell lymphoma patients (AACR 2023) - P1/2 | "Based on these promising data, MT-101 is being assessed in humans in the Phase 1, open-label, first-in-human trial in patients with refractory or relapsed T cell lymphoma, IMAGINE trial (NCT05138458)...In this subject, survival has been greater than 10 months, while the median overall survival of patients with R/R PTCL is 5.5 months. Continued patient enrollment and data collection is ongoing to confirm these observations."

Preclinical • Hematological Malignancies • Lymphoma • Melanoma • Oncology • Peripheral T-cell Lymphoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma • CD8

Myeloid Therapeutics Presents Late-Breaking Data on Multiple Platforms at the American Association for Cancer Research (AACR) 2023 Annual Meeting (PRNewswire) - P1/2 | N=40 | IMAGINE (NCT05138458) | Sponsor: Myeloid Therapeutics | "In a rodent model of melanoma (gp75+ B16/F10-OVA), Ly6C+ monocytes engineered with this receptor were able to phagocytose tumor cells and cross present antigen in vitro. In vivo infusion of engineered monocytes was associated with significant suppression of tumor growth....Based on these promising data, MT-101 is being assessed in humans in the Phase 1, open-label, first-in-human trial in patients with refractory or relapsed T cell lymphoma, IMAGINE trial....In the first 3 subjects, MT-101 was well-tolerated, with no evidence of CRS, ICANS, or infusion reactions. Examination of biomarkers by CyTOF in one subject showed changes in circulating leukocytes, including B cells. In this subject, survival has been greater than 10 months, while the median overall survival of patients with R/R PTCL is 5.5 months."

P1 data • Preclinical • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Melanoma • Non-Hodgkin’s Lymphoma • Oncology • Skin Cancer

Myeloid Therapeutics Announces FDA Fast Track Designation for MT-101 for the Treatment of CD5+ Relapsed/Refractory PTCL (PRNewswire) - "Myeloid Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MT-101 in patients with refractory or relapsed CD5+ peripheral T cell lymphoma (PTCL)....'IMAGINE, a Phase 1/2 trial assessing safety, tolerability, and efficacy of MT-101 in this indication is open for enrollment and the initial data is very encouraging'."

Fast track designation • Trial status • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma

Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans (PRNewswire) - "Myeloid Therapeutics, Inc...announced the first patient dosed in the IMAGINE Study, a Phase 1/2 clinical study of MT-101, in patients with refractory or relapsed peripheral T cell lymphoma (PTCL), an aggressive form of non-Hodgkin lymphoma..."

Trial status • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma